CAP-232

N/A

Report date: 2022/11/25 18:10:20
NME

Base Information

Drug NameCAP-232
Drug Alias NameTLN-232TT-232CAP-232
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionSomatostatin receptor 4 agonistsPyruvate kinase isozymes R/L inhibitorsPyruvate kinase isozymes M1/M2 inhibitors
TargetsPyruvate kinase isozymes R/LPyruvate kinase isozymes M1/M2Somatostatin receptor 4
Therapy Area/IndicationsCarcinoma, Renal CellMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesFrance
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBiostatinHungarian Academy Of Sciences
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesThallion Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsCarcinoma, Renal CellMelanoma

Other Information

ATC CodeN/A
Related LinksWikipedia